New cancer clinical trial: A Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2 ) Inhibitor SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Published on: July 27, 2018 at 12:00PM
Condition:   Relapsed or Refractory Mature Lymphoid Neoplasms
Intervention:   Drug: SHR2554
Sponsors:   Jiangsu HengRui Medicine Co., Ltd.;   Beijing Cancer Hospital
Not yet recruiting
https://ift.tt/2mOnQk4